在心力衰竭患者中使用药物治疗的趋势,其中包括保存的喷射分数
Munaza Riaz1,2, Steven M Smith1,3, Eric A Dietrich4
1Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.
概括
在心力衰竭中使用药物的使用与保存的喷射分数 (HFpEF) 从2008年到2020年转移. ангиотензин受体-neprilysin 抑制剂 (RNAI) 和 SGLT2 抑制剂的使用量增加,而像狄戈辛和酸盐这样的旧药物使用量下降.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭影响了所有心力衰竭患者的一半.
- 对HFpEF的治疗指南已经发展,但药物利用趋势仍未得到充分研究.
- 了解这些趋势对于优化HFpEF管理至关重要.
研究的目的:
- 分析2008年至2020年期间高度皮肤病患者使用各种药物治疗的趋势.
- 在13年的时间内确定关键HFpEF药物的处方模式的变化.
主要方法:
- 一项使用MarketScan®商业和医疗保险补充数据库 (2007-2020) 的回顾性队列研究.
- 纳入标准侧重于被诊断为HFpEF的患者.
- 对11种药物类别的药物利用率在初始HFpEF诊断后90天内进行评估.
主要成果:
- 从2008年到2020年,血管新生素受体-尼普利辛抑制剂 (RNAI),血管新生素受体阻断剂 (ARB),阿尔多素受体对抗剂 (ARA),通道阻断剂 (CCB) 和-葡萄糖共传递-2 抑制剂 (SGLT2i) 的使用显著增加.
- 相反,血管激素转化酶抑制剂 (ACEI),消毒素,酸盐,利尿剂和β抑制剂的使用减少.
- 固酶-5抑制剂 (PDE5I) 显示使用率稳定.
结论:
- 该研究观察到HFpEF患者在13年内药物治疗利用率的显著变化.
- 采用RNAI和SGLT2i等新药的数量显著增加.
- 相反,在HFpEF管理中,几种传统药物的使用,包括狄戈辛和酸盐,下降了.
更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164